Showing results filtered by:
2 Results
NIAID, in coordination with the HHS Biomedical Advanced Research and Development Authority (BARDA), supported preclinical and clinical research to develop several antibody-based therapeutics as anthrax antitoxins. One such product is Anthim, a human monoclonal antibody produced by Elusys Therapeutics, Inc.
Last Reviewed: November 19, 2024
We use a multidisciplinary approach encompassing virology, immunology, and epidemiology to investigate protection against and susceptibility to emerging viruses to inform safe and effective deployments of vaccines. Our primary expertise is in seroepidemiology, and our research focuses dengue, which we believe serves as a model pathogen for other complex, immune-evasive viruses.
Last Reviewed: February 23, 2023